| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
μ Opioid Receptor/MOR
|
|---|---|
| ln Vivo |
In a dose-dependent manner, CTOP TFA (0-0.5 nmol, ICV, once) counteracts the analgesic effect[1]. Animals exposed to CTOP TFA (0–2 nmol, ICV, once) experience withdrawal hypothermia and body weight loss[ 1]. In the nucleus accumbens, CTOP TFA (0–1.5 nmol per side, Intra-VTA injection) raises extracellular dopamine levels and dose-dependently increases locomotor activity[2].
|
| Animal Protocol |
Animal/Disease Models: Male CFLP mice (25-30 g)[ 1]
Doses: 0, 0.001, 0.05, 0.075, 0.1, and 0.5 nmol (made up in artificial cerebrospinal fluid (CSF) and kept in plastic tubes at -25℃ until use) Route of Administration: Intracerebroventricular (icv) administration, once Experimental Results: Antagonized the analgesic effect in a dose-dependent manner, antagonized the induced hypermotility in a dose-dependent manner. Animal/Disease Models: Male CFLP mice (25-30 g, Acute dependence to morphine was induced by a single dependence-inducing (100 mg/ kg) dose of morphine-HC1)[1] Doses: 0, 0.001, 0.05, 0.2, and 2 nmol Route of Administration: Intracerebroventricular (icv) administration, once Experimental Results: diminished the body temperature in a dose-dependent manner, and caused withdrawal hypothermia and a loss of body weight in animals. Animal/Disease Models: Long-Evans hooded rats (12, male, 350-450 g)[2] Doses: 0, 0.015, 0.15, and 1.5 nmol per side Route of Administration: Intra-VTA (ventral tegmental area) injection Experimental Results: Enhanced extracellular dopamine levels in the nucleus accumbens, dose-dependently increased activity, whereas had no effect on feeding and drinking behavior. |
| References |
| Molecular Formula |
C52H68F3N11O13S2
|
|---|---|
| Molecular Weight |
1176.28
|
| Related CAS # |
CTOP;103429-31-8
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~42.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (85.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8501 mL | 4.2507 mL | 8.5014 mL | |
| 5 mM | 0.1700 mL | 0.8501 mL | 1.7003 mL | |
| 10 mM | 0.0850 mL | 0.4251 mL | 0.8501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
